


## APPENDIX 15: CLINICAL FOREST PLOTS

1.1	<i>Psychosocial interventions</i> .....	1
1.1.1	Behavioural therapies aimed at communication.....	1
1.1.2	Behavioural therapies aimed at behaviour management .....	1
1.1.3	Cognitive behavioural therapies.....	2
1.1.4	Leisure programmes.....	3
1.1.5	Social learning interventions .....	4
1.1.6	Supported employment programmes.....	4
1.1.7	Support for families and carers.....	6
1.2	<i>Biomedical interventions</i> .....	8
1.2.1	Antipsychotics .....	8
1.2.2	Anticonvulsants .....	15
1.2.3	Drugs affecting cognition .....	16
1.2.4	Adrenocorticotrophic hormones .....	17
1.2.5	Secretin .....	18
1.2.6	Stimulants.....	19
1.2.7	Antidepressants.....	20
1.2.8	Restrictive diets, vitamins, minerals and supplements .....	22
1.3	<i>Settings for care</i> .....	25
1.3.1	Community based teams .....	25
1.3.2	Residential accommodation and related services .....	25

### 1.1 PSYCHOSOCIAL INTERVENTIONS


#### 1.1.1 Behavioural therapies aimed at communication

##### 1.1.1.1 Natural language teaching compared with analog language teaching for communication in adults with autism




#### 1.1.2 Behavioural therapies aimed at behaviour management

### 1.1.2.1 Independence training versus no treatment control for activities of daily living (showering) in adults with intellectual disability




### 1.1.2.2 Behavioural weight control programme versus no treatment control for self care (weight loss) in adults with intellectual disability




## 1.1.3 Cognitive behavioural therapies


### 1.1.3.1 Cognitive behavioural therapy versus treatment as usual for severity of coexisting OCD symptoms in adults with autism




### 1.1.3.2 Anti-victimization skills training versus waitlist control for anti-victimization skills (continuous measure) in adults with intellectual disability



### 1.1.3.3 Anti-victimization skills training versus waitlist control for anti-victimization skills (dichotomous measure) in adults with intellectual disability




### 1.1.3.4 Anger management versus waitlist control or treatment as usual for anger in adults with intellectual disability




## 1.1.4 Leisure programmes

### 1.1.4.1 Leisure programme compared with waitlist control for quality of life in adults with autism




### 1.1.4.2 Leisure programme compared with waitlist control for emotion recognition in adults with autism




## 1.1.5 Social learning interventions


### 1.1.5.1 Emotion recognition training compared with treatment as usual for emotion recognition in adults with autism



### 1.1.5.2 Social skills group compared with waitlist control for social interaction in adolescents with autism




### 1.1.5.3 Social skills group compared with treatment as usual for maladaptive behaviour in adults with intellectual disability




## 1.1.6 Supported employment programmes


### 1.1.6.1 Supported employment compared with sheltered workshop for autistic behaviours in adults with autism




### 1.1.6.2 Supported employment compared with sheltered workshop for quality of life in adults with autism



### 1.1.6.3 Supported employment compared with waitlist control for executive function in adults with autism




### 1.1.6.4 Supported employment compared with treatment-as-usual control for job placements in adults with autism




## 1.1.7 Support for families and carers


### 1.1.7.1 Psychoeducational group permanency planning intervention compared with treatment as usual for knowledge and awareness about planning in mothers of adults with intellectual disability




### 1.1.7.2 Psychoeducational group permanency planning intervention compared with treatment as usual for competence and confidence to plan in mothers of adults with intellectual disability




### 1.1.7.3 Psychoeducational group permanency planning intervention compared with treatment as usual for appraisals of the planning process by mothers of adults with intellectual disability



**1.1.7.4 Psychoeducational group permanency planning intervention compared with treatment as usual for intermediate planning behaviours of mothers of adults with intellectual disability**




**1.1.7.5 Psychoeducational group permanency planning intervention compared with treatment as usual for residential and legal planning of mothers of adults with intellectual disability**




## 1.2 BIOMEDICAL INTERVENTIONS

### 1.2.1 Antipsychotics


#### 1.2.1.1 Risperidone compared with placebo for challenging behaviour (irritability & aggression) in adults with autism



#### 1.2.1.2 Risperidone compared with placebo for autistic core symptoms (repetitive behaviour) in adults with autism




#### 1.2.1.3 Risperidone compared with placebo for autistic behaviours in adults with autism







### 1.2.1.4 Risperidone compared with placebo for symptom severity/improvement in adults with autism




### 1.2.1.5 Risperidone compared with placebo for challenging behaviour in adults with intellectual disability




### 1.2.1.6 Risperidone compared with placebo for aggression in adults with intellectual disability




### 1.2.1.7 Risperidone compared with placebo for symptom severity/improvement in adults with intellectual disability




### 1.2.1.8 Risperidone compared with placebo for quality of life in adults with intellectual disability




### 1.2.1.9 Haloperidol compared with placebo for autistic behaviours in adolescents with autism




### 1.2.1.10 Haloperidol compared with placebo for side effects (global) in adolescents with autism




### 1.2.1.11 Haloperidol compared with placebo for challenging behaviour in adults with intellectual disability




**1.2.1.12 Haloperidol compared with placebo for aggression in adults with intellectual disability**




**1.2.1.13 Haloperidol compared with placebo for symptom severity/improvement in adults with intellectual disability**




**1.2.1.14 Haloperidol compared with placebo for quality of life in adults with intellectual disability**




### 1.2.1.15 Risperidone compared with haloperidol for challenging behaviour in adults with intellectual disability




### 1.2.1.16 Risperidone compared with haloperidol for aggression in adults with intellectual disability




### 1.2.1.17 Risperidone compared with haloperidol for symptom severity/improvement in adults with intellectual disability




### 1.2.1.18 Risperidone compared with haloperidol for quality of life in adults with intellectual disability




### 1.2.1.19 Zuclopenthixol compared with placebo for challenging behaviour (aggression; endpoint data) in adults with intellectual disability




### 1.2.1.20 Zuclopenthixol compared with placebo for challenging behaviour (irritability; change from baseline data) in adults with intellectual disability




### 1.2.1.21 Zuclopenthixol compared with placebo for symptom severity/improvement (endpoint data) in adults with intellectual disability




### 1.2.1.22 Zuclopenthixol compared with placebo for symptom severity/improvement (change from baseline data) in adults with intellectual disability




### 1.2.1.23 Prothipendyl compared with placebo for symptom severity/improvement in adults with intellectual disability



### 1.2.1.24 Cis(z)-clopenthixol compared with haloperidol for symptom severity/improvement in adults with intellectual disability




### 1.2.1.25 Cis(z)-clopenthixol compared with haloperidol for side effects in adults with intellectual disability




## 1.2.2 Anticonvulsants


### 1.2.2.1 Valproate compared with placebo for challenging behaviour (irritability; continuous data) in children with autism




### 1.2.2.2 Valproate compared with placebo for challenging behaviour (irritability; dichotomous data) in children with autism




### 1.2.2.3 Valproate compared with placebo for challenging behaviour (aggression) in children with autism



### 1.2.2.4 Valproate compared with placebo for symptom severity/improvement in children with autism




### 1.2.2.5 Valproate compared with placebo for side effects in children with autism




## 1.2.3 Drugs affecting cognition

### 1.2.3.1 Donepezil hydrochloride compared with placebo for autistic behaviours in children with autism




### 1.2.3.2 Amantadine hydrochloride compared with placebo for challenging behaviour (irritability) in children with autism






## 1.2.4 Adrenocorticotrophic hormones


### 1.2.4.1 ORG 2766 compared with placebo for challenging behaviour (social withdrawal) in children with autism



### 1.2.4.2 ORG 2766 compared with placebo for challenging behaviour (social isolation) in children with autism




### 1.2.4.3 ORG 2766 compared with placebo for symptom severity/improvement in children with autism




## 1.2.5 Secretin


### 1.2.5.1 Secretin compared with placebo for core autistic symptoms of communication and symbolic behaviour in children with autism



### 1.2.5.2 Secretin compared with placebo for autistic behaviours in children with autism




### 1.2.5.3 Secretin compared with placebo for challenging behaviour in children with autism




## 1.2.6 Stimulants


### 1.2.6.1 Methylphenidate compared with placebo for coexisting hyperactivity in children with autism



### 1.2.6.2 Methylphenidate compared with placebo for the core autistic symptom of social interaction in children with autism




### 1.2.6.3 Methylphenidate compared with placebo for the core autistic symptom of repetitive behaviour in children with autism




## 1.2.7 Antidepressants


### 1.2.7.1 Clomipramine compared with placebo for autistic behaviours in adolescents with autism




### 1.2.7.2 Clomipramine compared with placebo for global side effects in adolescents with autism




### 1.2.7.3 Fluvoxamine compared with placebo for the core autistic symptom of repetitive behaviour in adults with autism




### 1.2.7.4 Fluvoxamine compared with placebo for autistic behaviours in adults with autism




### 1.2.7.5 Fluvoxamine compared with placebo for the challenging behaviour of aggression (change-from-baseline scores) in adults with autism




### 1.2.7.6 Fluvoxamine compared with placebo for maladaptive behaviour (change-from-baseline scores) in adults with autism



### 1.2.7.7 Fluvoxamine compared with placebo for symptom severity/improvement (dichotomous measure) in adults with autism




### 1.2.7.8 Fluvoxamine compared with placebo for symptom severity/improvement (continuous measure) in adults with autism




## 1.2.8 Restrictive diets, vitamins, minerals and supplements


### 1.2.8.1 Gluten-and-casein-free diet compared with treatment as usual for autistic behaviours (social isolation and bizarre behaviour) in children with autism




### 1.2.8.2 Digestive enzyme supplementation compared with placebo for core autistic symptoms (communication) in children with autism




### 1.2.8.3 Digestive enzyme supplementation compared with placebo for challenging behaviour in children with autism




### 1.2.8.4 Digestive enzyme supplementation compared with placebo for gastrointestinal symptoms in children with autism




### 1.2.8.5 L-carnosine compared with placebo for autistic behaviours in children with autism




### 1.2.8.6 L-carnosine compared with placebo for symptom severity/improvement in children with autism




### 1.2.8.7 Micronutrient compared with standard medication for autistic behaviours in children with autism



### 1.2.8.8 Micronutrient compared with standard medication for challenging behaviour (irritability) in children with autism



**1.2.8.9** Micronutrient compared with standard medication for symptom severity/improvement in children with autism






## 1.3 SETTINGS FOR CARE


### 1.3.1 Community based teams

#### 1.3.1.1 Current living compared with developmental centre group home training environments for teaching community living skills to adults with intellectual disability




### 1.3.2 Residential accommodation and related services


#### 1.3.2.1 Residential institution compared with community housing for adaptive behaviour in adults with intellectual disability




#### 1.3.2.2 Residential institution compared with community housing for residential satisfaction (total score) in adults with intellectual disability




### 1.3.2.3 Residential institution compared with community housing for residential satisfaction with social life in adults with intellectual disability




### 1.3.2.4 Residential institution compared with community housing for residential satisfaction with autonomy in adults with intellectual disability




### 1.3.2.5 Residential institution compared with community housing for social skills in adults with intellectual disability




### 1.3.2.6 Residential institution compared with community housing for social inclusion of adults with intellectual disability




### 1.3.2.7 Residential institution compared with community housing for social inclusion of adults with intellectual disability




### 1.3.2.8 Residential institution compared with community housing for quality of life of adults with intellectual disability




### 1.3.2.9 Small residential homes compared with institution for quality of life of adults with intellectual disability




### 1.3.2.10 Small residential homes compared with institution for choice making of adults with intellectual disability




### 1.3.2.11 Small residential homes compared with institution for community inclusion of adults with intellectual disability




### 1.3.2.12 Small residential homes compared with institution for family contact of adults with intellectual disability




### 1.3.2.13 Dispersed supported housing compared with residential group home for social inclusion of adults with intellectual disability



### 1.3.2.14 Group homes compared with semi-independent apartments for resident satisfaction of adults with intellectual disability



**1.3.2.15** Placement into a transitional developmental centre before placement into intermediate care facilities versus direct placement into intermediate care facilities for adaptive behaviour of adults with intellectual disability



**1.3.2.16** Person-centred compared with system-centred planning for movement into the community of adults with intellectual disability

